Who Owns Voraxaze?
Voraxaze (glucarpidase) is owned by SERB Pharmaceuticals, a private specialty pharmaceutical company headquartered in Paris, France. The drug, used to rapidly reduce toxic methotrexate levels in patients with impaired kidney function, was originally developed by Protherics, came to SERB through its March 2021 acquisition of BTG Specialty Pharmaceuticals from Boston Scientific, and remains the only FDA-approved treatment of its kind.
Voraxaze Timeline
Who Owns Voraxaze?
- Parent Company: SERB Pharmaceuticals
- Ownership Type: Brand division
- Acquisition Year: 2021
- Company Type: Privately Held
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Voraxaze | SERB Pharmaceuticals | Brand division |
Where to Buy
Disclosure: We may earn commission from purchases
Voraxaze on AmazonAdvertisement
History of Voraxaze
- Founded: 2012
- Founders: Protherics (developer, later BTG)
- Acquired by SERB Pharmaceuticals: 2021
Voraxaze (glucarpidase, also known as carboxypeptidase-G2) was developed by Protherics, a British biotech, as a rescue therapy for patients experiencing toxic methotrexate levels. High-dose methotrexate is used in cancers like leukemia and lymphoma, but in patients with kidney impairment the drug clears too slowly, reaching toxic concentrations that leucovorin alone cannot overcome. Glucarpidase works by enzymatically cleaving methotrexate, converting it to inactive metabolites and rapidly reducing plasma levels.
The drug received European approval in 2008 and FDA approval in January 2012 for patients with toxic methotrexate concentrations due to impaired kidney function. It filled a niche but critical gap: for these rare emergencies, there was previously no effective rescue beyond supportive care and leucovorin.
Ownership changes followed the acquiring-company chain: Protherics was acquired by BTG in 2009, Boston Scientific bought BTG in 2019, and SERB took the pharmaceutical business in 2021. Through all transitions, Voraxaze remained the only approved glucarpidase, a sole-source product with no direct competitors. Under SERB it continues as a marketed rare-disease therapy, distributed through hospital and specialty pharmacy channels for methotrexate toxicity emergencies.
Advertisement
About SERB Pharmaceuticals
Who owns SERB Pharmaceuticals?
SERB Pharmaceuticals is a privately held company. Jeremie Urbain serves as chairman. The company does not publicly disclose its shareholder structure, and it is not owned by a larger pharmaceutical corporation.
Is SERB Pharmaceuticals publicly traded?
No. SERB is a private company. Its shares do not trade on any stock exchange.
When was SERB founded?
The original SERB (Société d'Études et de Recherches Biologiques) was founded in Paris in 1951. The modern company took shape through the 2021 acquisition of BTG Specialty Pharmaceuticals and a 2022 rebrand unifying SERB, BTG Specialty Pharmaceuticals, and Veriton Pharma.
Who makes Voraxaze?
Voraxaze (glucarpidase) is made by SERB Pharmaceuticals. SERB acquired the product in March 2021 as part of its approximately $800 million purchase of BTG Specialty Pharmaceuticals from Boston Scientific. BTG had originally launched Voraxaze in 2012.
Advertisement
What does SERB Pharmaceuticals make?
More than 70 medicines across two franchises: emergency medicine and antidotes (CroFab, DigiFab, Voraxaze, Radiogardase, and CBRN countermeasures) and rare disease treatments in oncology, neurology, and metabolic disorders, including Danyelza.
Where is SERB based?
The company is headquartered in Paris, France. Its US operations run through BTG Pharmaceuticals in West Conshohocken, Pennsylvania, and it has manufacturing and R&D sites in Wales, Australia, Utah, and France.
- Founded: 1951
- Headquarters: Paris, France
- Company Type: Privately Held
- Revenue: Approximately $400 million (estimated, private company)
- Employees: More than 600
Where Is Voraxaze Made / Based?
- Headquarters: Paris, France
- Manufacturing / Operations: United States, Europe
Voraxaze Categories & Tags
Voraxaze Ownership: Pros & Cons
Advantages
- +Sole approved glucarpidase gives Voraxaze a complete monopoly in its indication
- +SERB's specialty-pharma focus means dedicated commercial and medical attention to a niche product
- +Orphan drug pricing and defined hospital demand provide stable, high-margin revenue
- +Acquisition into SERB's antidote portfolio creates portfolio synergies with CroFab and DigiFab
Considerations
- -The addressable market is inherently tiny: rare emergencies in methotrexate patients
- -Dependence on hospital stocking decisions and clinician awareness of its availability
- -Private equity ownership introduces eventual exit or portfolio reshuffling risk
- -No pipeline growth: the product is a single indication with no expansion pathway
Advertisement
Frequently Asked Questions About Voraxaze
Sources & Further Reading
- Voraxaze Official Website
- SERB Pharmaceuticals
- Boston Scientific to Sell BTG Pharma to SERB — press coverage December 2020
- FDA Voraxaze Approval
Advertisement
Competitors to Voraxaze
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Mckesson | USA | 1994 | Mass market | United states | All-ages | |
| Labcorp | USA | 2010 | Mass market | United states | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsBiologics by McKesson
Owned by McKesson Corporation
Independent specialty pharmacy providing personalized patient care for oncology and rare disease treatments owned by McKesson Corporation.
specialty-pharmacyoncologyrare-disease
Healthcare PharmaceuticalsInvitae
Owned by Labcorp Holdings Inc.
Medical genetics testing brand acquired by Labcorp for $239 million in 2024, focused on oncology, rare disease, and reproductive health.
genetic-testingdiagnosticsoncology
Competitive Analysis
Market Positioning: Voraxaze competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Voraxaze
Looking for brands with different ownership structures? These similar brands are not owned by SERB Pharmaceuticals, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsGE HealthCare
Owned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
healthcare-technologymedical-imagingdiagnostics
Publicly Traded
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsHCA Healthcare
Owned by HCA Healthcare, Inc.
HCA Healthcare is the flagship brand of the largest U.S. for-profit hospital operator, a network of 190 hospitals and about 2,500 ambulatory sites across 19 states and England.
hospitalshealthcareemergency-care
Publicly Traded
HCA Healthcare operates independently without a large parent corporation.
Healthcare PharmaceuticalsPfizer
Owned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
pharmaceuticalvaccinesmedicines
Publicly Traded
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsPhilips
Owned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
healthcare-technologyelectronicsmedical-devices
Publicly Traded
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsRegeneron
Owned by Regeneron Pharmaceuticals, Inc.
Biotechnology brand of Regeneron Pharmaceuticals, developer of Eylea, Dupixent, and Libtayo, headquartered in Tarrytown, New York.
biotechnologypharmaceuticalseylea
Publicly Traded
Regeneron operates independently without a large parent corporation.
Healthcare PharmaceuticalsSmith+Nephew
Owned by Smith+Nephew plc
British medical technology company founded in 1856, reporting $6.16 billion in FY2025 revenue across orthopaedics, sports medicine, and advanced wound management, listed on the London Stock Exchange.
medical-devicesorthopedicswound-care
Publicly Traded
Smith+Nephew operates independently without a large parent corporation.
Jobs at SERB Pharmaceuticals
Advertisement
Latest News About Voraxaze
Related Articles About Voraxaze
View more articles
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
Health
Health Insurance Brand Ownership: The Big Players
UnitedHealth is #1 ($112B Q2 revenue, 26% MA share). CVS/Aetna is #3 ($106.1B Q2). Humana is #2 in MA (19.8%). Elevance is #2 by enrollment. Discover health insurance brand ownership. Explore our database.
Who Brands StaffNov 11, 2026
UnitedhealthAetnaCvs Health
Health
Organic Food Brand Ownership: Still Independent?
Annie's is General Mills ($820M). Cascadian Farm is General Mills (since 1999). Stonyfield is Lactalis (via Danone, $875M). Kashi is Kellogg's. Honest Tea was Coca-Cola (discontinued). Explore our database.
Who Brands StaffNov 9, 2026
Organic FoodAnniesCascadian Farm
Advertisement
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization